{"title":"纳米粒子作为治疗血吸虫感染的有效药物：系统综述","authors":"Pegah Shakib PhD , Masoomeh Zivdari MSc , Amal Khudair Khalaf PhD , Abdolrazagh Marzban PhD , Mazdak Ganjalikhani-Hakemi PhD , Jahanbakhsh Parvaneh MD , Hossein Mahmoudvand PhD , Kourosh Cheraghipour PhD","doi":"10.1016/j.curtheres.2023.100715","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes of the genus <em>Schistosoma</em>. The current drugs for treating schistosomiasis are associated with some side effects.</p></div><div><h3>Objective</h3><p>The aim of this systematic study was an overview of the treatment of diseases caused by <em>Schistosoma</em> based on nanoparticles.</p></div><div><h3>Methods</h3><p>In the present systematic research with keywords “<em>Schistosoma</em>”, “parasitism”, “anti-<em>Schistosoma</em> activity”, “nanoparticles”, “metal nanoparticles”, “silver nanoparticles”, “gold nanoparticles”, “polymer nanoparticles”, “PLGA nanoparticles”, “nanoemulsions”, “<em>in vitro</em>”, and “<em>in vivo</em>” from five English-language databases, including ScienceDirect, europePMC, PubMed, Scopus, Ovid, and Cochrane were searched from 2000 to 2022 by 2 researchers.</p></div><div><h3>Results</h3><p>In the initial search, 250 studies were selected. Based on the inclusion and exclusion criteria, 27 articles were finally selected after removing duplicate, unrelated, and articles containing full text. In present article, the most nanoparticles used against <em>Schistosoma</em> were gold nanoparticles (22%).</p></div><div><h3>Conclusions</h3><p>The results indicate the high potential of various nanoparticles, including metal nanoparticles, against <em>Schistosoma</em>. Also, the remarkable anti-schistosomal activity of nanoparticles suggests their use in different fields to eliminate this pathogenic microorganism so that it can be used as an effective candidate in the preparation of anti-schistosomal compounds because these compounds have fewer side effects than chemical drugs. <em>Ther Res Clin Exp</em>. 2023; XX:XXX–XXX).</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"99 ","pages":"Article 100715"},"PeriodicalIF":1.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nanoparticles as Potent Agents for Treatment of Schistosoma Infections: A Systematic Review\",\"authors\":\"Pegah Shakib PhD , Masoomeh Zivdari MSc , Amal Khudair Khalaf PhD , Abdolrazagh Marzban PhD , Mazdak Ganjalikhani-Hakemi PhD , Jahanbakhsh Parvaneh MD , Hossein Mahmoudvand PhD , Kourosh Cheraghipour PhD\",\"doi\":\"10.1016/j.curtheres.2023.100715\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes of the genus <em>Schistosoma</em>. The current drugs for treating schistosomiasis are associated with some side effects.</p></div><div><h3>Objective</h3><p>The aim of this systematic study was an overview of the treatment of diseases caused by <em>Schistosoma</em> based on nanoparticles.</p></div><div><h3>Methods</h3><p>In the present systematic research with keywords “<em>Schistosoma</em>”, “parasitism”, “anti-<em>Schistosoma</em> activity”, “nanoparticles”, “metal nanoparticles”, “silver nanoparticles”, “gold nanoparticles”, “polymer nanoparticles”, “PLGA nanoparticles”, “nanoemulsions”, “<em>in vitro</em>”, and “<em>in vivo</em>” from five English-language databases, including ScienceDirect, europePMC, PubMed, Scopus, Ovid, and Cochrane were searched from 2000 to 2022 by 2 researchers.</p></div><div><h3>Results</h3><p>In the initial search, 250 studies were selected. Based on the inclusion and exclusion criteria, 27 articles were finally selected after removing duplicate, unrelated, and articles containing full text. In present article, the most nanoparticles used against <em>Schistosoma</em> were gold nanoparticles (22%).</p></div><div><h3>Conclusions</h3><p>The results indicate the high potential of various nanoparticles, including metal nanoparticles, against <em>Schistosoma</em>. Also, the remarkable anti-schistosomal activity of nanoparticles suggests their use in different fields to eliminate this pathogenic microorganism so that it can be used as an effective candidate in the preparation of anti-schistosomal compounds because these compounds have fewer side effects than chemical drugs. <em>Ther Res Clin Exp</em>. 2023; XX:XXX–XXX).</p></div>\",\"PeriodicalId\":10920,\"journal\":{\"name\":\"Current Therapeutic Research-clinical and Experimental\",\"volume\":\"99 \",\"pages\":\"Article 100715\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Therapeutic Research-clinical and Experimental\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0011393X23000243\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X23000243","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Nanoparticles as Potent Agents for Treatment of Schistosoma Infections: A Systematic Review
Background
Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes of the genus Schistosoma. The current drugs for treating schistosomiasis are associated with some side effects.
Objective
The aim of this systematic study was an overview of the treatment of diseases caused by Schistosoma based on nanoparticles.
Methods
In the present systematic research with keywords “Schistosoma”, “parasitism”, “anti-Schistosoma activity”, “nanoparticles”, “metal nanoparticles”, “silver nanoparticles”, “gold nanoparticles”, “polymer nanoparticles”, “PLGA nanoparticles”, “nanoemulsions”, “in vitro”, and “in vivo” from five English-language databases, including ScienceDirect, europePMC, PubMed, Scopus, Ovid, and Cochrane were searched from 2000 to 2022 by 2 researchers.
Results
In the initial search, 250 studies were selected. Based on the inclusion and exclusion criteria, 27 articles were finally selected after removing duplicate, unrelated, and articles containing full text. In present article, the most nanoparticles used against Schistosoma were gold nanoparticles (22%).
Conclusions
The results indicate the high potential of various nanoparticles, including metal nanoparticles, against Schistosoma. Also, the remarkable anti-schistosomal activity of nanoparticles suggests their use in different fields to eliminate this pathogenic microorganism so that it can be used as an effective candidate in the preparation of anti-schistosomal compounds because these compounds have fewer side effects than chemical drugs. Ther Res Clin Exp. 2023; XX:XXX–XXX).
期刊介绍：
We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics.
CTR encourages and supports the submission of manuscripts describing:
• Interventions designed to understand or improve human health, disease treatment or disease prevention;
• Studies that focus on problems that are uncommon in resource-rich countries;
• Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing);
• Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English;
• Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
